Last $6.40 USD
Change Today -0.10 / -1.54%
Volume 35.8K
TLOG On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

tetralogic pharmaceuticals c (TLOG) Snapshot

Open
$6.53
Previous Close
$6.50
Day High
$6.53
Day Low
$6.27
52 Week High
01/15/14 - $14.75
52 Week Low
03/28/14 - $5.89
Market Cap
142.6M
Average Volume 10 Days
68.5K
EPS TTM
--
Shares Outstanding
22.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for TETRALOGIC PHARMACEUTICALS C (TLOG)

Related News

No related news articles were found.

tetralogic pharmaceuticals c (TLOG) Related Businessweek News

No Related Businessweek News Found

tetralogic pharmaceuticals c (TLOG) Details

TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical company in the United States. The company focuses on discovering and developing novel small molecule therapeutics that mimic novel second mitochondrial activator of caspases to cause or enable abnormal cells, which are resistant to the body’s immune system to self-destruct. Its clinical-stage product candidate, Birinapant, is in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The company’s clinical and pre-clinical programs comprise an ongoing Phase I/II clinical trial of birinapant as a single agent in various blood cancers; a Phase I/II completed clinical trial of birinapant administered with irinotecan in colorectal cancer; and a Phase I/II clinical trial of birinapant administered with conatumumab in ovarian cancer, as well as an intention to start Phase I clinical trial in hepatitis B virus. It has collaboration with Amgen, Inc. for exploring the combination of birinapant administered with Amgen’s TRAIL receptor agonist antibody, conatumumab. The company was formerly known as Gentara Corporation and changed its name to TetraLogic Pharmaceuticals Corporation in January 2006. TetraLogic Pharmaceuticals Corporation was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

20 Employees
Last Reported Date: 03/19/14
Founded in 2001

tetralogic pharmaceuticals c (TLOG) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $175.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $141.2K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $137.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $315.2K
Compensation as of Fiscal Year 2013.

tetralogic pharmaceuticals c (TLOG) Key Developments

Shape Pharmaceuticals, Inc., TetraLogic Pharmaceuticals Corporation - M&A Call

To review the transaction and related matters of executed definitive agreement to acquire Shape Pharmaceuticals, Inc. by TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Announces Publication of Preclinical Characterization of Birinapant

TetraLogic Pharmaceuticals Corporation announced that data published in the April issue of Molecular Cancer Therapeutics further advances the preclinical characterization of its lead SMAC-Mimetic birinapant, which is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors. The publication titled "Birinapant (TL32711), a Bivalent SMAC Mimetic, Targets TRAF2-Associated cIAPs, Abrogates TNF-Induced NF-[kappa]B Activation, and Is Active in Patient-Derived Xenograft Models," will appear in the April edition of Molecular Cancer Therapeutics. The experiments described in the publication demonstrate that birinapant bound to the BIR3 domains of cIAP1, cIAP2, XIAP, and the BIR domain of ML-IAP in vitro and induced the autoubiquitylation and proteasomal degradation of cIAP1 and cIAP2, resulting in induction of tumor cell death. Birinapant preferentially targeted the TRAF2-associated cIAP1 and cIAP2 with subsequent inhibition of TNF-induced NF-[kappa]B activation. The activity of a variety of chemotherapeutic cancer drugs was potentiated by birinapant, and tumor growth in multiple primary patient--derived xenotransplant models was inhibited by birinapant at well-tolerated doses.

TetraLogic Pharmaceuticals Corporation(NasdaqGM:TLOG) added to Russell 2000 Index

TetraLogic Pharmaceuticals Corporation will be added to the Russell 2000 Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TLOG:US $6.40 USD -0.10

TLOG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TLOG.
View Industry Companies
 

Industry Analysis

TLOG

Industry Average

Valuation TLOG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TETRALOGIC PHARMACEUTICALS C, please visit www.tetralogicpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.